Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

Recruiting now · Phase 1

Conditions studied: Obesity

In brief

The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.

Key facts

Study ID

NCT07153172

Run by

Novo Nordisk A/S

People needed

91

Starts

2025-08-06

Expected to finish

2027-09-15

Last updated by the study team

2026-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• Male or female (sex at birth).
• Age 18 years or above at the time of signing the informed consent.
• Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment [above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)].

You may not qualify if…

• The study has no exclusion criteria.

Where it is running

• Syneos Health Clinique — Québec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.